Sign in
Taking people in United StatesPhase 1/2

A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

Key facts

Who runs it
Coherus Oncology, Inc.
Where
Seattle, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
12 people, planned
Started
Nov 2026
Expected to end
Aug 2028
Type of study
Interventional
Treatments tested
  • Tagmokitug
  • Pasritamig
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
  • Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment; mCRPC:
  • Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is not permitted
  • Measurable Castration-resistant Prostate Cancer (mCRPC) as defined by PCWG3 criteria. Participant must have mCRPC that is metastatic either to bone, lymph node (LN), or both without clear evidence of either measurable or nonmeasurable metastasis to visceral organs at the time of screening scan
  • Participants must have been previously treated with at least 1 prior androgen-receptor pathway inhibitor (ARPI) (ie, abiraterone acetate, enzalutamide, apalutamide, darolutamide)
  • Participants must have received at least one prior taxane therapy unless the participant is ineligible or refused. Participants must not have received other prior cytotoxic chemotherapy (ie, cisplatin, carboplatin, etoposide)
  • Prior orchiectomy or medical castration. Participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog with testosterone ≤50 nanogram per deciliter (ng/dL) prior to the first dose of study drug and must continue this therapy throughout the treatment phase

Who cannot take part

  • Prior exposure to anti-CCR8 antibody agents
  • Prior allogeneic hematological stem cell transplantation or organ transplantation; mCRPC:
  • Any known prior history of brain metastases of prostate cancer (PCa)
  • Treatment with antineoplastic therapy (including but not limited to cytotoxic chemotherapy, biologic agents, and investigational agents) other than ADT or ARPI within 28 days or <5× the elimination half-life (t½), whichever is earlier, before Day 1
  • Prior exposure to a T cell engager or human kallikrein 2 (KLK2) targeted therapy
  • Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study; Additional protocol-defined inclusion and exclusion criteria apply
  • History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Solid tumor

This trial is currently available in United States.

  • Fred Hutchinson Cancer CenterSeattle, United StatesContact: Clinical Operations TeamTaking people

About the trial

What the trial wants to find out

The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.

The group in the trial

  • mCRPC: Tagmokitug + PasritamigTreatment being tested

    Treatment: Tagmokitug and Pasritamig

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Criteria questions
Built from NCT07945821, who can take part
Record updated
18 November 2026